Dissecting isoform selectivity of PI3K inhibitors: the role of non-conserved residues in the catalytic pocket
Open Access
- 27 August 2008
- journal article
- research article
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 414 (3), 383-390
- https://doi.org/10.1042/bj20080512
Abstract
The last few years have seen the identification of numerous small molecules that selectively inhibit specific class I isoforms of PI3K (phosphoinositide 3-kinase), yet little has been revealed about the molecular basis for the observed selectivities. Using site-directed mutagenesis, we have investigated one of the areas postulated as being critical to the observed selectivity. The residues Thr886 and Lys890 of the PI3Kγ isoform project towards the ATP-binding pocket at the entrance to the catalytic site, but are not conserved. We have made reciprocal mutations between those residues in the β isoform (Glu858 and Asp862) and those in the α isoform (His855 and Gln859) and evaluated the potency of a range of reported PI3K inhibitors. The results show that the potencies of β-selective inhibitors TGX221 and TGX286 are unaffected by this change. In contrast, close analogues of these compounds, particularly the α-isoform-selective compound (III), are markedly influenced by the point mutations. The collected data suggests two distinct binding poses for these inhibitor classes, one of which is associated with potent PI3Kβ activity and is not associated with the mutated residues, and a second that, in accord with earlier hypotheses, does involve this pair of non-conserved amino acids at the catalytic site entrance and contributes to the α-isoform-selectivity of the compounds studied.Keywords
This publication has 23 references indexed in Scilit:
- Furan-2-ylmethylene Thiazolidinediones as Novel, Potent, and Selective Inhibitors of Phosphoinositide 3-Kinase γJournal of Medicinal Chemistry, 2006
- A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin SignalingCell, 2006
- Study on improving the selectivity of compounds that inhibit two PI3Ks (gamma and delta)Journal of Molecular Modeling, 2006
- Phosphoinositide 3-kinases as drug targets in cancerCurrent Opinion in Pharmacology, 2005
- Oncogenic Mutations of PIK3CA in Human CancersCell Cycle, 2004
- PDE2 inhibition by the PI3 kinase inhibitor LY294002 and analoguesBioorganic & Medicinal Chemistry Letters, 2004
- Selective role of PI3Kδ in neutrophil inflammatory responsesBiochemical and Biophysical Research Communications, 2003
- Synthesis and Function of 3-Phosphorylated Inositol LipidsAnnual Review of Biochemistry, 2001
- Structural Determinants of Phosphoinositide 3-Kinase Inhibition by Wortmannin, LY294002, Quercetin, Myricetin, and StaurosporineMolecular Cell, 2000
- Central Role for G Protein-Coupled Phosphoinositide 3-Kinase γ in InflammationScience, 2000